AI Engines For more Details: Perplexity Kagi Labs You
Edema: Spironolactone is often prescribed to treat edema associated with conditions such as congestive heart failure, liver cirrhosis, and nephrotic syndrome. It works by reducing fluid accumulation in the body through its diuretic effect.
Hypertension: Spironolactone can help lower blood pressure by promoting the excretion of excess sodium and water while conserving potassium. It is sometimes used alone or in combination with other antihypertensive medications to manage hypertension.
Heart Failure: Spironolactone is used as an adjunctive treatment for heart failure to reduce symptoms and improve survival rates. It may be particularly beneficial in patients with severe heart failure or those who cannot tolerate angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).
Hormonal Disorders: Spironolactone has antiandrogenic properties, meaning it blocks the effects of male hormones like testosterone. It is used off-label to treat hormonal disorders such as polycystic ovary syndrome (PCOS) and hirsutism (excessive hair growth) in women by reducing androgen levels.
Acne: Due to its antiandrogenic effects, spironolactone is sometimes prescribed off-label to treat acne in women, especially when hormonal factors contribute to the development of acne lesions.
Female Pattern Hair Loss: Spironolactone may also be used off-label to treat female pattern hair loss (androgenetic alopecia) by reducing the activity of androgens that contribute to hair thinning and loss.
Primary Aldosteronism: Spironolactone is effective in treating primary aldosteronism, a condition characterized by excessive production of aldosterone hormone by the adrenal glands. It helps reduce aldosterone levels and correct associated fluid and electrolyte imbalances.
Polycystic Kidney Disease: In some cases, spironolactone may be used to manage fluid retention associated with polycystic kidney disease (PKD), a genetic disorder characterized by the growth of fluid-filled cysts in the kidneys.
Electrolyte Imbalance: Spironolactone helps maintain electrolyte balance by sparing potassium while promoting the excretion of sodium and water. However, excessive potassium retention can occur in some individuals, especially those with kidney dysfunction or concurrent use of other potassium-sparing drugs.
Side Effects: Common side effects of spironolactone may include increased urination, dizziness, headache, gastrointestinal upset, breast tenderness or enlargement (gynecomastia) in men, irregular menstrual periods, and electrolyte imbalances. Rare but serious side effects may include hyperkalemia (high potassium levels), allergic reactions, and kidney dysfunction.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Bacteroides uniformis | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Parabacteroides distasonis | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Dorea | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Collinsella | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Veillonella | genus | Decreases |
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Enterocloster | genus | Decreases |
0 | 1 | Blautia | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Bifidobacterium adolescentis | species | Decreases |
1 | 0 | Blautia obeum | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
1 | 0 | Dorea formicigenerans | species | Decreases |
1 | 0 | Bifidobacterium longum | species | Decreases |
1 | 0 | Enterocloster bolteae | species | Decreases |
1 | 0 | Veillonella parvula | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
1 | 0 | Parabacteroides distasonis | species | Decreases |
1 | 0 | Collinsella aerofaciens | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | [Ruminococcus] torques | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
Acne | 0.3 | -0.3 | |
ADHD | 4.1 | 0.3 | 12.67 |
Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
Allergic Rhinitis (Hay Fever) | 3 | 2.8 | 0.07 |
Allergies | 5.9 | 1.7 | 2.47 |
Allergy to milk products | 1.3 | 1.6 | -0.23 |
Alopecia (Hair Loss) | 1.5 | 1.5 | |
Alzheimer's disease | 5.4 | 5.1 | 0.06 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2 | 0.6 | 2.33 |
Ankylosing spondylitis | 4 | 1.1 | 2.64 |
Anorexia Nervosa | 1.3 | 2.3 | -0.77 |
Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
Asthma | 5.4 | 2.3 | 1.35 |
Atherosclerosis | 1.9 | 1.9 | 0 |
Atrial fibrillation | 2.8 | 1.9 | 0.47 |
Autism | 7.6 | 7.5 | 0.01 |
Autoimmune Disease | 1.2 | 1 | 0.2 |
Barrett esophagus cancer | 0.6 | 0.3 | 1 |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 2.6 | 2.6 | |
Bipolar Disorder | 2.1 | 1.1 | 0.91 |
Brain Trauma | 0.9 | 1.1 | -0.22 |
Breast Cancer | 1.2 | 1.2 | |
Cancer (General) | 0.9 | 2.3 | -1.56 |
Carcinoma | 4.6 | 2.3 | 1 |
Celiac Disease | 2.9 | 3.4 | -0.17 |
Cerebral Palsy | 1.4 | 1 | 0.4 |
Chronic Fatigue Syndrome | 4.3 | 4.7 | -0.09 |
Chronic Kidney Disease | 4 | 1.6 | 1.5 |
Chronic Lyme | 0.6 | 0.8 | -0.33 |
Chronic Obstructive Pulmonary Disease (COPD) | 2.6 | 1.7 | 0.53 |
Chronic Urticaria (Hives) | 1.9 | 0.2 | 8.5 |
Coagulation / Micro clot triggering bacteria | 1.9 | 1 | 0.9 |
Cognitive Function | 2.2 | 1.6 | 0.38 |
Colorectal Cancer | 6.8 | 2.5 | 1.72 |
Constipation | 1.5 | 0.7 | 1.14 |
Coronary artery disease | 2 | 1.8 | 0.11 |
COVID-19 | 9.4 | 9 | 0.04 |
Crohn's Disease | 7.8 | 3.7 | 1.11 |
Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
cystic fibrosis | 1.1 | 1.9 | -0.73 |
d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
deep vein thrombosis | 2 | 1.1 | 0.82 |
Denture Wearers Oral Shifts | 2 | 2 | |
Depression | 9.5 | 6.6 | 0.44 |
Dermatomyositis | 0.3 | 0.3 | 0 |
Eczema | 1.9 | 2.2 | -0.16 |
Endometriosis | 3.2 | 2 | 0.6 |
Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
Epilepsy | 3.6 | 1.5 | 1.4 |
erectile dysfunction | 1.4 | 0.3 | 3.67 |
Fibromyalgia | 3.4 | 1.1 | 2.09 |
Functional constipation / chronic idiopathic constipation | 5.4 | 2.5 | 1.16 |
gallstone disease (gsd) | 3.2 | 1.1 | 1.91 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.7 | 1.2 | 0.42 |
Generalized anxiety disorder | 2.7 | 1.6 | 0.69 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 0.9 | 0.2 | 3.5 |
Graves' disease | 1.6 | 2.7 | -0.69 |
Gulf War Syndrome | 0.6 | 1.1 | -0.83 |
Halitosis | 1.8 | 0.3 | 5 |
Hashimoto's thyroiditis | 2.9 | 1.4 | 1.07 |
Heart Failure | 3.8 | 1 | 2.8 |
hemorrhagic stroke | 1.3 | 1.3 | |
Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
High Histamine/low DAO | 2 | 0.3 | 5.67 |
hypercholesterolemia (High Cholesterol) | 1 | 1 | |
hyperglycemia | 2.2 | 1.1 | 1 |
Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
hypersomnia | 0.7 | -0.7 | |
hypertension (High Blood Pressure | 3.8 | 4.6 | -0.21 |
Hypothyroidism | 0.7 | -0.7 | |
Hypoxia | 3.6 | 0.3 | 11 |
IgA nephropathy (IgAN) | 1.6 | 3.6 | -1.25 |
Inflammatory Bowel Disease | 8.7 | 7 | 0.24 |
Insomnia | 2.1 | 1.8 | 0.17 |
Intelligence | 1.4 | 1.4 | |
Intracranial aneurysms | 1.1 | 0.3 | 2.67 |
Irritable Bowel Syndrome | 6.8 | 4.1 | 0.66 |
ischemic stroke | 2.8 | 1.4 | 1 |
Liver Cirrhosis | 7.1 | 3.6 | 0.97 |
Long COVID | 6.2 | 6.5 | -0.05 |
Low bone mineral density | 0.8 | -0.8 | |
Lung Cancer | 1.1 | 0.7 | 0.57 |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 1.5 | 0.3 | 4 |
ME/CFS with IBS | 1 | 1.7 | -0.7 |
ME/CFS without IBS | 1 | 2.1 | -1.1 |
membranous nephropathy | 0.3 | 0.3 | |
Menopause | 1.9 | 0.5 | 2.8 |
Metabolic Syndrome | 6.6 | 6.7 | -0.02 |
Mood Disorders | 9.1 | 5.2 | 0.75 |
multiple chemical sensitivity [MCS] | 1.1 | 0.1 | 10 |
Multiple Sclerosis | 6.5 | 4.1 | 0.59 |
Multiple system atrophy (MSA) | 1.1 | 0.4 | 1.75 |
myasthenia gravis | 0.9 | 0.7 | 0.29 |
neuropathic pain | 0.3 | 2.9 | -8.67 |
Neuropathy (all types) | 0.7 | 2.1 | -2 |
neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.5 | 3.5 | 0.57 |
NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
Obesity | 8.3 | 6.9 | 0.2 |
obsessive-compulsive disorder | 5.4 | 2.3 | 1.35 |
Osteoarthritis | 2.7 | 0.9 | 2 |
Osteoporosis | 2.2 | 1.3 | 0.69 |
pancreatic cancer | 1.2 | 0.3 | 3 |
Parkinson's Disease | 7 | 5.3 | 0.32 |
Polycystic ovary syndrome | 5.3 | 2.3 | 1.3 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
primary biliary cholangitis | 1.2 | 1.4 | -0.17 |
Primary sclerosing cholangitis | 2.9 | 2.1 | 0.38 |
Psoriasis | 2.9 | 1.7 | 0.71 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.6 | 3.4 | 0.94 |
Rosacea | 0.5 | 0.7 | -0.4 |
Schizophrenia | 6.2 | 2.5 | 1.48 |
scoliosis | 0.6 | 0.3 | 1 |
Sjögren syndrome | 2.5 | 2.6 | -0.04 |
Sleep Apnea | 1.6 | 1.3 | 0.23 |
Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.9 | 0.5 | 2.8 |
Stress / posttraumatic stress disorder | 3.2 | 1.9 | 0.68 |
Systemic Lupus Erythematosus | 3.8 | 1.6 | 1.37 |
Tic Disorder | 0.9 | 1.2 | -0.33 |
Tourette syndrome | 0.9 | 0.3 | 2 |
Type 1 Diabetes | 3.2 | 3.7 | -0.16 |
Type 2 Diabetes | 7.4 | 6.4 | 0.16 |
Ulcerative colitis | 6.4 | 5.5 | 0.16 |
Unhealthy Ageing | 5 | 1.6 | 2.13 |
Vitiligo | 1.8 | 0.9 | 1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]